2. Search Result
Search Result
Results for "

C. parvum

" in MedChemExpress (MCE) Product Catalog:

6

Inhibitors & Agonists

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-103583
    KDU731

    		PI4K Parasite Infection
    KDU731, an orally active C. parvum PI4K inhibitor with an IC50 value of 25 nM, blocks Cryptosporidium infection in vitro and in vivo . KDU731 is a promising agent candidate for the treatment of diarrhea caused by Cryptosporidium and meets a broad range of safety .
    KDU731
  • HY-128398
    CpCDPK1/TgCDPK1-IN-2

    		Parasite Infection
    CpCDPK1/TgCDPK1-IN-2 (Compound 7r) is a CpCDPK1 and TgCDPK1 inhibitor with IC50 values of 12 and 5 nM, respectively. CpCDPK1/TgCDPK1-IN-2 can be used in the research of apicomplexan protozoa-related diseases, such as the research of T. gondii, C. parvum and C. hominus infection .
    CpCDPK1/TgCDPK1-IN-2
  • HY-128399
    CpCDPK1/TgCDPK1-IN-3

    		Parasite Infection
    CpCDPK1/TgCDPK1-IN-3 (Compound 20) is a CpCDPK1 and TgCDPK1 inhibitor with IC50 values of 0.003 and 0.0036 µM, respectively. CpCDPK1/TgCDPK1-IN-3 can be used in the research of apicomplexan protozoa-related diseases, such as the research of T. gondii, C. parvum and C. hominus infection .
    CpCDPK1/TgCDPK1-IN-3
  • HY-136307S
    Tizoxanide-d4 glucuronide

    		Parasite Infection
    Tizoxanide-d4 glucuronide is the deuterium labeled Tizoxanide glucuronide. Tizoxanide glucuronide is the metabolite of Nitazoxanide (HY-B0217) and is cell-permeable to inhibit asexual and sexual stages development of parasite C. parvum[1].
    Tizoxanide-d4 glucuronide
  • HY-118421
    Nullscript

    		Parasite HDAC Infection
    Nullscript is a negative control for Scriptaid. Nullscript is a known inactive analog of Scriptaid . Scriptaid is a representative HDAC inhibitor . Nullscript inhibits Cryptosporidium (C. parvum) growth with the IC50 value of 2.1 μM .
    Nullscript
  • HY-121495
    BKI-1369

    		Parasite Infection
    BKI-1369 is a bumped kinase inhibitor (BKI). BKI-1369 increases human Ether-a-go-go-related gene (hERG)-inhibitory activity with an IC50 of 1.52 μM. BKI-1369 reduces the parasite burden and diseases severity in the gnotobiotic pig model. BKI-1369 has been well characterized for potency, stability, metabolism, toxicity, pharmacokinetics and is potent against C. parvum in infected mice and calves .
    BKI-1369

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: